Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Other financing activities (2018 - 2025)

Dexcom (DXCM) has disclosed Other financing activities for 8 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly Other financing activities fell 18.75% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.0 million through Dec 2025, up 46.15% year-over-year, with the annual reading at -$7.0 million for FY2025, 46.15% up from the prior year.
  • Other financing activities for Q4 2025 was -$1.9 million at Dexcom, down from -$1.7 million in the prior quarter.
  • The five-year high for Other financing activities was $4.9 million in Q4 2023, with the low at -$8.7 million in Q1 2024.
  • Average Other financing activities over 5 years is -$2.3 million, with a median of -$1.5 million recorded in 2024.
  • The sharpest move saw Other financing activities crashed 3850.0% in 2021, then surged 590.0% in 2023.
  • Over 5 years, Other financing activities stood at -$800000.0 in 2021, then decreased by 25.0% to -$1.0 million in 2022, then soared by 590.0% to $4.9 million in 2023, then plummeted by 132.65% to -$1.6 million in 2024, then dropped by 18.75% to -$1.9 million in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at -$1.9 million, -$1.7 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.